Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Early Phase 1

Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase

NCT01722916 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to find how much hyaluronidase should be used when receiving injections of fillers.

Conditions Studied

Interventions

  • DRUG Hyaluronidase

Study Locations (1)

Illinois

  • Northwestern University Department of Dermatology — Chicago

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2012-10
Est. Completion 2025-12
Phase Early Phase 1

Sponsor

Northwestern University

1,033 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01722916

The ClinicalTrials.gov registry entry for NCT01722916 describes a study currently listed as active not recruiting. It is categorized as Early Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,033 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Drug Safety appearing as the primary indexed condition, and to 1 intervention — of which Hyaluronidase is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01722916 reports 1 study location spanning 1 distinct geographic area — top geographies include Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01722916 about?

NCT01722916 is a clinical study titled "Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase". The purpose of this study is to find how much hyaluronidase should be used when receiving injections of fillers.

What is the current status of trial NCT01722916?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2012-10. Estimated completion is 2025-12.

What conditions does trial NCT01722916 study?

This clinical trial studies the following conditions: Drug Safety. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01722916?

The interventions under investigation include: Hyaluronidase (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01722916?

This trial is sponsored by Northwestern University, which has 1,033 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01722916 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial